Semglee®
ACTIVE PRINCIPLE:
Insulin glargine
INDICATION:
Diabetes mellitus type 2
DATE:
23/03/2018
STATUS:
Authorized
Biosimilar medicine authorized by the European Commission
ACTIVE PRINCIPLE:
Insulin glargine
INDICATION:
Diabetes mellitus type 2
DATE:
23/03/2018
STATUS:
Authorized
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.